AGIO Shares Outstanding History
Below is a table of the AGIO shares outstanding history going back to 7/24/2013:

Date AGIO Shares Outstanding
7/24/201329.38M
9/1/201331.07M
11/1/201331.17M
3/14/201431.59M
8/6/201434.46M
11/6/201434.68M
2/20/201537.22M
5/8/201537.30M
8/5/201537.44M
11/4/201537.64M
2/23/201637.85M
5/5/201637.92M
8/5/201638.05M
10/31/201642.01M
2/14/201742.23M
5/1/201748.20M
8/4/201748.39M
10/30/201748.75M
2/9/201857.33M
4/30/201857.61M
7/30/201857.99M
10/29/201858.18M
2/8/201958.40M
4/26/201958.71M
7/26/201958.75M
8/14/20199.19M
10/25/201958.88M
2/13/202068.51M
4/24/202068.89M
7/24/202069.11M
10/30/202069.26M
2/18/202169.60M

Also see: AGIO Market Cap History
AGIO YTD Return
AGIO Historical Shares Outstanding:
+12.05% CAGR
AGIO Historical Shares Outstanding: +12.05% CAGR

Mouse over chart for data details
7/24/2013 ...2/18/2021
Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. Co.'s product, TIBSOVO® (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. Co.'s other product is IDHIFA® (enasidenib) for patients with R/R AML and an IDH2 mutation. Co.'s pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a. We show 32 historical shares outstanding datapoints in our coverage of AGIO's shares outstanding history.

Understanding the changing numbers of AGIO shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AGIO versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AGIO by allowing them to research AGIO shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AGIO:
AGIO SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Agios Pharmaceuticals (AGIO) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

AGLE Shares Outstanding History
AGN Shares Outstanding History
AGRX Shares Outstanding History
AGTC Shares Outstanding History
AHPI Shares Outstanding History
AIMT Shares Outstanding History
AIQ Shares Outstanding History
AKAO Shares Outstanding History
AKBA Shares Outstanding History
AKCA Shares Outstanding History
More Healthcare companies »

 

AGIO Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.